Moderna Doses First Patient In Phase 1 mRNA-4200 Trial
The mRNA-4200 candidate primes the immune system against tumor antigens in ten solid-tumor types, alone and with Keytruda.
- Trial NCT06880549 aims to enroll 42 patients across sites in Michigan, Texas and Utah.
- A parallel arm tests mRNA-4106, Moderna's related cancer-antigen candidate, as a standalone therapy.
- Primary endpoints track dose-limiting toxicities and adverse events through two years, three months.
Why it matters: A dose-finding study of forty-two patients measures whether the injection is safe, not whether it cures anything.
Moderna (press release via ACCESS Newswire) / ClinicalTrials.gov NCT06880549 ↗ · Jul 21, 20267/21/26 · ✓ Checked✓ Check